Monitor for potential follow-up selling or commentary ahead of next earnings; coordinated C-suite exits may signal caution despite no public negative news. Compare with historical patterns, if this deviates from routine selling, it could foreshadow downside risk.
PTCT drugs
PTCT drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $63.33entry
- T+1 · 9mo ago −0.81%α +0.51% · $62.82
- T+5 · 8mo ago +0.05%α +2.29% · $63.36
- T+20 · 8mo ago +7.01%α +10.80% · $67.77
- T+60 · 6mo ago +16.53%α +5.23% · $73.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three corporate insiders at PTC Therapeutics sold shares in a coordinated 7-day window, including the Chief Medical Officer and Chief Technical Operations Officer, totaling $1.29 million in open-market transactions. The sales represent a modest but notable insider selling cluster, with executives and a director reducing holdings at current market prices.
Key Financial Metrics
Key Facts
- EVP & Chief Medical Officer Scott Golden sold 10,000 shares for $633,800 in an open-market transaction.
- Director Stephanie Okey sold 6,333 shares for $401,385.54 in an open-market transaction.
- Chief Technical Operations Officer Neil Almstead sold 3,989 shares for $252,822.82 in an open-market transaction.
- All transactions occurred on 2026-03-05 at $63.38 per share, totaling $1.288 million in aggregate.
- Total value of the cluster is approximately 0.025% of the company's $5.2B market cap, modest in scale but notable due to participation by C-suite executives.
Financial Impact
$1.288 million in insider selling, representing 0.025% of market capitalization
Risk Factors
- Perception of insider lack of confidence, especially with Chief Medical Officer selling.
- Potential for negative sentiment amplification if no fundamental explanation is provided.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (3 trades, 7d window) | cluster-PTCT-1773091238112 |
Track record
29 reports on PTCT
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
- Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
- Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers